{"success":true,"data":{"pressRelease":{"id":"177032","rtpr_id":"nGNX6PmmWv-20261022","ticker":"NRX","exchange":"","all_tickers":["NRX"],"title":"NurExone Demonstrates Scalable Exosome Production, Supporting Its Modular Manufacturing Strategy and Commercial Growth","author":"Globe Newswire","published_at":"2026-10-22T12:29:00.124Z","article_body":"TORONTO and HAIFA, Israel, Oct. 22, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic\nInc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the\n“Company”), a biopharmaceutical company developing exosome-based\nregenerative therapies for central nervous system injuries, today announced\nthat it doubled exosome production by successfully operating two bioreactors\nin parallel, while maintaining the same overall production time, process\nconsistency and comparable exosome quality.   The achievement marks an\nimportant step in NurExone’s strategy to build scalable exosome\nmanufacturing capabilities through its wholly owned U.S. subsidiary, Exo-Top\nInc. (“Exo-Top”), and its manufacturing collaboration with Made\nScientific.\n\nNurExone is pursuing a modular approach that enables manufacturing capacity to\nexpand by adding standardized production units in parallel (scaling out\napproach), rather than engineering larger bioreactor vessels (scaling up\napproach). This strategy has the potential to protect capital investments,\naccelerate development timelines, and allow production to match commercial\ndemand, subject to successful validation and implementation.\n\n“Our goal is to make increasing exosome production straightforward and\nrobust,” said Dr. Tali Kizhner, Director of Research and Development at\nNurExone. “We have invested hundreds of hours in studying and optimizing our\nmanufacturing process. This run shows that we successfully replicated that\nprocess to increase output while ensuring manufacturing of high-quality\nproduct, with similar characteristics and critical quality attributes (CQAs).\nThe achieved milestone provides us a strong foundation for expanding\nproduction capabilities even further.”\n\nTable 1: Comparative Quality and Potency Metrics Across Production Runs\n\n Product characteristic                                                Single Run A      Single Run B      Parallel Run (Two bioreactors)      \n Particle size (nm)                                                    140–145           130–145           135–140                             \n Surface electrical charge (mV)                                        −44.75            −45.6             −49.8                               \n Identity markers (CD9, CD63, CD81, TSG101)                            Detected          Detected          Detected                            \n Purity (Protein impurities removed)                                   >95%              >95%              >95%                                \n Anti-inflammatory activity (i)                                        <10⁹              <10⁹              <10⁹                                \n Relative Exosome Yield (above 10 (13)exosomes per single bioreactor)  100%              100%              200%                                \n\nAs shown in Table 1, the exosomes produced in the parallel run retained\ncomparable physical characteristics, the same identifying proteins and\nanti-inflammatory activity, providing initial evidence that greater output can\nbe achieved while maintaining consistency.\n\n“Scalable manufacturing is critical in positioning NurExone as a leader in\nthis rapidly evolving exosome-based field. Demonstrating that two bioreactors\ncan operate in parallel to double yield while maintaining process consistency\nstrengthens our ability to respond to future demand and achieve market\nleadership,” said Dr. Lior Shaltiel, Chief Executive Officer of NurExone.\n“Through Exo-Top and our U.S. manufacturing collaborations, we are building\nthe high-efficiency capabilities required to support both our internal\ntherapeutic pipeline and potential business-to-business commercial\nopportunities for naïve exosomes.”\n\nSupporting Therapeutic Development and Commercial Opportunities\n\nNurExone is pursuing a dual-track strategy that combines the development of\nregulated exosome-based therapies with commercial opportunities for naïve\nmesenchymal stromal cell-derived exosomes through Exo-Top.\n\nIts lead therapeutic candidate, ExoPTEN, is being developed for acute spinal\ncord injury and optic nerve damage. In parallel, Exo-Top is advancing\nmanufacturing and commercial collaborations involving naïve exosomes for\npotential applications beyond the Company’s drug development pipeline.\n\nAbout NurExone\n\nNurExone is a TSX Venture Exchange (“TSXV”), OTCQB, and Frankfurt-listed\nbiotech company focused on developing regenerative exosome-based therapies for\ncentral nervous system injuries. Its lead product, ExoPTEN, has demonstrated\nstrong preclinical data supporting clinical potential in treating acute spinal\ncord and optic nerve damage. Regulatory milestones, including obtaining the\nOrphan Drug Designation from the U.S. FDA and European EMA, facilitate the\nCompany’s roadmap towards clinical trials in the U.S. and Europe.\nCommercially, the Company aims to offer solutions to companies interested in\nquality exosomes and minimally invasive targeted delivery systems for other\nindications. NurExone has established Exo-Top Inc., a U.S. subsidiary, to\nanchor its North American activity and growth strategy.\n\nFor additional information and a brief interview, please watch Who is\nNurExone?\n(https://www.globenewswire.com/Tracker?data=UzppMAmWoHvdfyNWPKaAP2sY8irRdQBdl6gTkVDsgPrAk2kzgmw-Lu4wj3_SnSnvpgHEC73SPkp17YfCj0eVgHIri2A2hi4n7PexdG9RNMzl6Tdkmw02bFpMWMaEkPvz9-9IiNJH-dtOo5g41WtSF8ysYsX5Ryi5T95KfJG83K3j8RdJU4zxJc5L-F60g8lAC5y15xrkTooGtoCkTbbmmi4V5ppotL6EnlLlx74epG_MRtA9IJC_ro4mhmSztAFlz5aez1hbl-pqoWSZB2Yp6kGOpOTkdTwMygODaU1sm6Wkeuk5xICbjdhGI360dEp2GPWyB4I6YnJX4JP146aafbWzuWA1KhQlC0PJQld5RLUXobrl_z04LhZ4AwVuNEhgsku8s5DgWeAw5q5dZUmSsvUA0rIGM7F8DYDa4AyFGYihQXdAE4o0_1dMorpVvJiwPJa5v-Zsc_Hzcz3D1sQBw1LM3AvGO6mo4DkVG-Ngd2oYgWRgE1MGHW9czxIWDxY8QqFAh09NlBTz6P_JdgYsdw==),\nvisit www.nurexone.com or follow NurExone on LinkedIn\n(https://www.globenewswire.com/Tracker?data=nHJKNARMXI4Zd5ICefV5odfBNK1FAz03mqKf3zA2mkrDiecVeW8tGRiWzMjbqMAP50vzWqbBYeXMtCz6vda85GY9QjDeJ7_JguGZGgckoVEp8EChTD543fP86_3vEm29UFmxNYtyDtNv8oghqgJOAih22Go1kouLb1SDMGzJeRbbSGB2kdjqqkTMfGRU_GUPhncYNN2CiL0OgYXIvMaXT48Wj8q_Qavu6jgqi-fdcDrsX1g4oOjbPINJdQQbJBmt9AxVs0qSnUV2tA0CjHWUj211iYVnB_wFtILLg2IMs-8TktQ1KHbx-ymV9XCz54YDV1nFyC9kD94g5GJURq5RxlEggYCSW-1u_tAofznRO8PVZH_dI7m_E9_GfkCL5RyWi-Mi7n2SSQgcui16zQ9-0Y_lNf7xdtvTeDMDUq6H6FhRVd0iGDBIDUvr5BaAkdVmVfUlw52L6TvhGpYTuxa2pllkoFdcSOwPLA_gHJ2321A=), X\n(formerly Twitter)\n(https://www.globenewswire.com/Tracker?data=SIr1D_I-byAp2CKYr1pEMvSJXBuAB-0HUAYuPCDT0clTfNkxdryyMB4hsEE-NQ4fZ-UzmaxTBRePgpNWgrgz46Rz6XujzZVbOUgjEM7FVoMxy91UgDKKC-t5_2Zep2ns_zWLijihqUpCqscL9-oVMCFeWxxKq84H6q-5TrTjxX5EQjzEbXTHtlUJ7f5xOPwgT6sPMEpJjz6xD1qC34lgHjG0fVkbeqMdEBrhROmuXqXmfnEQoCOnrdpfiQoIJhYlG4h9ad7KVNRHbJHRc_3xjIDT97M1gm9CHAysZ2Q3KdLzi7VGPR8-0_0mU3cmpyNlIPgMKskVAhVM7UtpIZUGTFK6yFM-A7zGUT5LPeep4b_UcEnu_4aX9MC2yKyO-N9eBdmooPO9jqARCZn--FW51GujXW4sjXXikYCTejoeCAaq-UpHQiG7Qx5ontq1epF0PzQByjNN0eVwTRT7N22XqT6Q1pI-Hd_iuapgej8lyeVwMgH5_gIJPkBuMpJ1pw3v), Facebook\n(https://www.globenewswire.com/Tracker?data=Orh81xSiOBKP70u-q8Qf7cP2tBA2q-A9LX83YXH6UTFPtTQx6SKZGV13cys8LRdqZtjUSzcM5cbdVzFtesg-EsEPX6YDQyEYbipWdq1rVDThrzDawQab8EcHA28a63HKsrl5qYGtgY2WvUcv7jPkvn1UybkhfrxN09DOW2Qhd4nmzdMq3Tql-Mk-wI6RlhhGY-nmP1TFMJ3MYR_hJl5Y53jSLiBsQzUnSckgz3diva4qWohTenjdapEi7of1UqvSCFoHF4tNp2-J7n3CNJwQEkVuYKDZf7IxkzZbBeIyDPglDh9l7kvE6oR8XNkjFXsXdfdNYOGWCflxX_kfAUn43hMCxDFuEqtZ3HBuRW6Dpb4N6eIKa8oFgZ6-VGvEZwXhO44CWgLlbG6_64ViZLpAmCtrGyM_yh5pAV4JGuN4s9A_3v7kXhHodHVr6NXWAxqSaetk9zB2L1HeQW3FvwRsfcgIdmQr9zjwacfO9VOy5Ac=),\nor YouTube\n(https://www.globenewswire.com/Tracker?data=F0dBTdMo_DJmypIwE-14RsmxvGJvlS_m3ctKWILyqwNEveA-7KkTI_JFW9QVGcuJbG7sTDk8wJq-EbwNQXn5wDFkqH2l5Jwxc4oKPWKr0LoKJuLTo7n6Y8malP3rMYMGvB-xu2WZhjKtzX0vggHmehSwFHB4VgWHmcgKYtnAAjUboMpmOYWPu3-AUFTdA3_F_svuXQUV-ax8B7h5Ym2cSNr_H0JcOGcGwEAT9wkbQBdtDTxGo5zV8I03tzJKkPdOgqa8DE-SE4QPMFGz-CUwyEqghmCcQhwKoTzOuc4m859O6rsd4XGwBIV0AlKqz7mo4GalLMwLAvJ5aMlnt8RIXo33q53kTD3ZAZzaleoic_R12jqcEfA0nkkzDoLK-u1g6yEwvwLnGvG9Gjs-3q7LimEFJCQN2iWaPh87w0-u-Xkup9XMAC9v8_5OVLIfUo2jaama469NdNtEQiiPxSo-KnRWyN7AX1Ltg1r2kTzWUrc=).\n\nFor more information, please contact:\n\nDr. Lior Shaltiel\nChief Executive Officer and Director\nPhone: +972-52-4803034\nEmail: info@nurexone.com\n\nRusso Partners LLC\nInvestor and Media Relations – United States\n215 Park Ave S, Suite 1905\nNew York, NY 10003\nPhone: 212-845-4200\nEmail: nurexone@russopartnersllc.com\n\nDr. Eva Reuter\nInvestor Relations - Germany\nPhone: +49-69-1532-5857\nEmail: e.reuter@dr-reuter.eu\n\nFORWARD-LOOKING STATEMENTS\n\nThis press release contains “forward-looking information” and\n“forward-looking statements” within the meaning of applicable Canadian\nsecurities laws (collectively, “forward-looking statements”).\nForward-looking statements are based on expectations, estimates and\nprojections as of the date of this press release and are generally\nidentifiable by words such as “may,” “will,” “could,”\n“should,” “expect,” “plan,” “intend,” “anticipate,”\n“believe,” “estimate,” “potential,” “continue,” “advance”\nand similar expressions.\n\nForward-looking statements in this press release include statements\nconcerning: the potential scalability, repeatability and consistency of the\nCompany’s modular exosome manufacturing approach; the potential to expand\nmanufacturing capacity by operating additional standardized production units\nin parallel; the potential technical, timing, capital and risk-management\nbenefits of that approach; the Company’s plans to validate, develop and\nexpand its manufacturing capabilities through Exo-Top and with third-party\ncollaborators, including Made Scientific; the ability of the Company’s\nmanufacturing capabilities to support its internal therapeutic pipeline and\npotential business-to-business supply opportunities; future demand for naïve\nexosomes; the continued development of ExoPTEN for acute spinal cord injury\nand optic nerve damage; and the Company’s broader development, regulatory,\nclinical and commercialization plans for exosome-based therapies, exosome\nproducts and targeted delivery systems.\n\nThese forward-looking statements are based on material assumptions including\nthat: the reported production-run data and the Company’s interpretation of\nthose data are accurate and complete; the parallel production results can be\nreproduced in additional runs and at greater scale; the selected analytical\nresults are appropriate indicators of product comparability; the Company will\nbe able to validate its processes and meet applicable quality, regulatory and\nmanufacturing standards; additional bioreactors, facilities, materials,\npersonnel, funding and collaborators will be available on acceptable terms;\narrangements with Made Scientific and other counterparties will progress as\ncontemplated; demand for naïve exosomes and related services will develop;\nand the Company will be able to advance ExoPTEN and its other programs as\ncurrently contemplated.\n\nForward-looking statements are subject to known and unknown risks,\nuncertainties and other factors that may cause actual results to differ\nmaterially, including: the preliminary and limited nature of the reported\nproduction results; the risk that the results will not be reproduced in\nadditional runs or at larger scale; variability inherent in biological\nmanufacturing; the risk that parallel production will not result in consistent\nquality attributes, regulatory acceptance, lower costs, shorter timelines or\nreduced operational risk; equipment, contamination, process-failure,\nsupply-chain, facility, personnel and quality-control risks; the need for\nfurther process development, validation and technology transfer; the inability\nto secure sufficient financing, materials, personnel, facilities or\ncollaborators; delays, changes or termination affecting arrangements with Made\nScientific or other counterparties; the absence of commercial orders or\nsufficient market demand; competition and technological change; regulatory,\nclinical-development, intellectual-property and commercialization risks; and\nthe risks discussed under the heading “Risk Factors” on pages 44 to 51 of\nthe Company’s annual information form dated August 27, 2024 and other\ncontinuous disclosure documents available under the Company’s SEDAR+\nprofile, copies of which are available under the Company’s SEDAR+ profile at\nwww.sedarplus.ca.\n\nThe production results described in this press release do not establish\ncommercial-scale manufacturing capability or regulatory compliance and should\nnot be interpreted as demonstrating that the Company can manufacture products\nconsistently at commercial scale. ExoPTEN is an investigational product\ncandidate, has not been approved for commercial use or for the treatment of\nany condition by any regulatory authority, and its safety and efficacy in\nhumans have not been established. Although the Company believes that the\nexpectations and assumptions reflected in the forward-looking statements are\nreasonable, there can be no assurance that the anticipated activities,\nbenefits, demand or results will occur or be achieved. Readers should not\nplace undue reliance on forward-looking statements. Forward-looking statements\nspeak only as of the date of this press release, and the Company disclaims any\nobligation to update or revise them except as required by applicable law.\n\nNeither TSXV nor its Regulation Services Provider (as that term is defined in\nthe policies of the TSXV) accepts responsibility for the adequacy or accuracy\nof this release.\n\n(i) Particle concentration (particles/mL) needed to reduce IL-6, an\ninflammatory signaling protein, by 50%. Lower concentrations indicate greater\npotency. The results are reported as thresholds, not exact values.\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/1514c671-cc84-4bcb-82d7-b834fce40882)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX6PmmWv-20261022","title":"NurExone Demonstrates Scalable Exosome Production, Supporting Its Modular Manufacturing Strategy and Commercial Growth","author":"Globe Newswire","ticker":"NRX","created":"2026-10-22T12:29:00.124Z","tickers":["NRX"],"exchange":"","article_body":"TORONTO and HAIFA, Israel, Oct. 22, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic\nInc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the\n“Company”), a biopharmaceutical company developing exosome-based\nregenerative therapies for central nervous system injuries, today announced\nthat it doubled exosome production by successfully operating two bioreactors\nin parallel, while maintaining the same overall production time, process\nconsistency and comparable exosome quality.   The achievement marks an\nimportant step in NurExone’s strategy to build scalable exosome\nmanufacturing capabilities through its wholly owned U.S. subsidiary, Exo-Top\nInc. (“Exo-Top”), and its manufacturing collaboration with Made\nScientific.\n\nNurExone is pursuing a modular approach that enables manufacturing capacity to\nexpand by adding standardized production units in parallel (scaling out\napproach), rather than engineering larger bioreactor vessels (scaling up\napproach). This strategy has the potential to protect capital investments,\naccelerate development timelines, and allow production to match commercial\ndemand, subject to successful validation and implementation.\n\n“Our goal is to make increasing exosome production straightforward and\nrobust,” said Dr. Tali Kizhner, Director of Research and Development at\nNurExone. “We have invested hundreds of hours in studying and optimizing our\nmanufacturing process. This run shows that we successfully replicated that\nprocess to increase output while ensuring manufacturing of high-quality\nproduct, with similar characteristics and critical quality attributes (CQAs).\nThe achieved milestone provides us a strong foundation for expanding\nproduction capabilities even further.”\n\nTable 1: Comparative Quality and Potency Metrics Across Production Runs\n\n Product characteristic                                                Single Run A      Single Run B      Parallel Run (Two bioreactors)      \n Particle size (nm)                                                    140–145           130–145           135–140                             \n Surface electrical charge (mV)                                        −44.75            −45.6             −49.8                               \n Identity markers (CD9, CD63, CD81, TSG101)                            Detected          Detected          Detected                            \n Purity (Protein impurities removed)                                   >95%              >95%              >95%                                \n Anti-inflammatory activity (i)                                        <10⁹              <10⁹              <10⁹                                \n Relative Exosome Yield (above 10 (13)exosomes per single bioreactor)  100%              100%              200%                                \n\nAs shown in Table 1, the exosomes produced in the parallel run retained\ncomparable physical characteristics, the same identifying proteins and\nanti-inflammatory activity, providing initial evidence that greater output can\nbe achieved while maintaining consistency.\n\n“Scalable manufacturing is critical in positioning NurExone as a leader in\nthis rapidly evolving exosome-based field. Demonstrating that two bioreactors\ncan operate in parallel to double yield while maintaining process consistency\nstrengthens our ability to respond to future demand and achieve market\nleadership,” said Dr. Lior Shaltiel, Chief Executive Officer of NurExone.\n“Through Exo-Top and our U.S. manufacturing collaborations, we are building\nthe high-efficiency capabilities required to support both our internal\ntherapeutic pipeline and potential business-to-business commercial\nopportunities for naïve exosomes.”\n\nSupporting Therapeutic Development and Commercial Opportunities\n\nNurExone is pursuing a dual-track strategy that combines the development of\nregulated exosome-based therapies with commercial opportunities for naïve\nmesenchymal stromal cell-derived exosomes through Exo-Top.\n\nIts lead therapeutic candidate, ExoPTEN, is being developed for acute spinal\ncord injury and optic nerve damage. In parallel, Exo-Top is advancing\nmanufacturing and commercial collaborations involving naïve exosomes for\npotential applications beyond the Company’s drug development pipeline.\n\nAbout NurExone\n\nNurExone is a TSX Venture Exchange (“TSXV”), OTCQB, and Frankfurt-listed\nbiotech company focused on developing regenerative exosome-based therapies for\ncentral nervous system injuries. Its lead product, ExoPTEN, has demonstrated\nstrong preclinical data supporting clinical potential in treating acute spinal\ncord and optic nerve damage. Regulatory milestones, including obtaining the\nOrphan Drug Designation from the U.S. FDA and European EMA, facilitate the\nCompany’s roadmap towards clinical trials in the U.S. and Europe.\nCommercially, the Company aims to offer solutions to companies interested in\nquality exosomes and minimally invasive targeted delivery systems for other\nindications. NurExone has established Exo-Top Inc., a U.S. subsidiary, to\nanchor its North American activity and growth strategy.\n\nFor additional information and a brief interview, please watch Who is\nNurExone?\n(https://www.globenewswire.com/Tracker?data=UzppMAmWoHvdfyNWPKaAP2sY8irRdQBdl6gTkVDsgPrAk2kzgmw-Lu4wj3_SnSnvpgHEC73SPkp17YfCj0eVgHIri2A2hi4n7PexdG9RNMzl6Tdkmw02bFpMWMaEkPvz9-9IiNJH-dtOo5g41WtSF8ysYsX5Ryi5T95KfJG83K3j8RdJU4zxJc5L-F60g8lAC5y15xrkTooGtoCkTbbmmi4V5ppotL6EnlLlx74epG_MRtA9IJC_ro4mhmSztAFlz5aez1hbl-pqoWSZB2Yp6kGOpOTkdTwMygODaU1sm6Wkeuk5xICbjdhGI360dEp2GPWyB4I6YnJX4JP146aafbWzuWA1KhQlC0PJQld5RLUXobrl_z04LhZ4AwVuNEhgsku8s5DgWeAw5q5dZUmSsvUA0rIGM7F8DYDa4AyFGYihQXdAE4o0_1dMorpVvJiwPJa5v-Zsc_Hzcz3D1sQBw1LM3AvGO6mo4DkVG-Ngd2oYgWRgE1MGHW9czxIWDxY8QqFAh09NlBTz6P_JdgYsdw==),\nvisit www.nurexone.com or follow NurExone on LinkedIn\n(https://www.globenewswire.com/Tracker?data=nHJKNARMXI4Zd5ICefV5odfBNK1FAz03mqKf3zA2mkrDiecVeW8tGRiWzMjbqMAP50vzWqbBYeXMtCz6vda85GY9QjDeJ7_JguGZGgckoVEp8EChTD543fP86_3vEm29UFmxNYtyDtNv8oghqgJOAih22Go1kouLb1SDMGzJeRbbSGB2kdjqqkTMfGRU_GUPhncYNN2CiL0OgYXIvMaXT48Wj8q_Qavu6jgqi-fdcDrsX1g4oOjbPINJdQQbJBmt9AxVs0qSnUV2tA0CjHWUj211iYVnB_wFtILLg2IMs-8TktQ1KHbx-ymV9XCz54YDV1nFyC9kD94g5GJURq5RxlEggYCSW-1u_tAofznRO8PVZH_dI7m_E9_GfkCL5RyWi-Mi7n2SSQgcui16zQ9-0Y_lNf7xdtvTeDMDUq6H6FhRVd0iGDBIDUvr5BaAkdVmVfUlw52L6TvhGpYTuxa2pllkoFdcSOwPLA_gHJ2321A=), X\n(formerly Twitter)\n(https://www.globenewswire.com/Tracker?data=SIr1D_I-byAp2CKYr1pEMvSJXBuAB-0HUAYuPCDT0clTfNkxdryyMB4hsEE-NQ4fZ-UzmaxTBRePgpNWgrgz46Rz6XujzZVbOUgjEM7FVoMxy91UgDKKC-t5_2Zep2ns_zWLijihqUpCqscL9-oVMCFeWxxKq84H6q-5TrTjxX5EQjzEbXTHtlUJ7f5xOPwgT6sPMEpJjz6xD1qC34lgHjG0fVkbeqMdEBrhROmuXqXmfnEQoCOnrdpfiQoIJhYlG4h9ad7KVNRHbJHRc_3xjIDT97M1gm9CHAysZ2Q3KdLzi7VGPR8-0_0mU3cmpyNlIPgMKskVAhVM7UtpIZUGTFK6yFM-A7zGUT5LPeep4b_UcEnu_4aX9MC2yKyO-N9eBdmooPO9jqARCZn--FW51GujXW4sjXXikYCTejoeCAaq-UpHQiG7Qx5ontq1epF0PzQByjNN0eVwTRT7N22XqT6Q1pI-Hd_iuapgej8lyeVwMgH5_gIJPkBuMpJ1pw3v), Facebook\n(https://www.globenewswire.com/Tracker?data=Orh81xSiOBKP70u-q8Qf7cP2tBA2q-A9LX83YXH6UTFPtTQx6SKZGV13cys8LRdqZtjUSzcM5cbdVzFtesg-EsEPX6YDQyEYbipWdq1rVDThrzDawQab8EcHA28a63HKsrl5qYGtgY2WvUcv7jPkvn1UybkhfrxN09DOW2Qhd4nmzdMq3Tql-Mk-wI6RlhhGY-nmP1TFMJ3MYR_hJl5Y53jSLiBsQzUnSckgz3diva4qWohTenjdapEi7of1UqvSCFoHF4tNp2-J7n3CNJwQEkVuYKDZf7IxkzZbBeIyDPglDh9l7kvE6oR8XNkjFXsXdfdNYOGWCflxX_kfAUn43hMCxDFuEqtZ3HBuRW6Dpb4N6eIKa8oFgZ6-VGvEZwXhO44CWgLlbG6_64ViZLpAmCtrGyM_yh5pAV4JGuN4s9A_3v7kXhHodHVr6NXWAxqSaetk9zB2L1HeQW3FvwRsfcgIdmQr9zjwacfO9VOy5Ac=),\nor YouTube\n(https://www.globenewswire.com/Tracker?data=F0dBTdMo_DJmypIwE-14RsmxvGJvlS_m3ctKWILyqwNEveA-7KkTI_JFW9QVGcuJbG7sTDk8wJq-EbwNQXn5wDFkqH2l5Jwxc4oKPWKr0LoKJuLTo7n6Y8malP3rMYMGvB-xu2WZhjKtzX0vggHmehSwFHB4VgWHmcgKYtnAAjUboMpmOYWPu3-AUFTdA3_F_svuXQUV-ax8B7h5Ym2cSNr_H0JcOGcGwEAT9wkbQBdtDTxGo5zV8I03tzJKkPdOgqa8DE-SE4QPMFGz-CUwyEqghmCcQhwKoTzOuc4m859O6rsd4XGwBIV0AlKqz7mo4GalLMwLAvJ5aMlnt8RIXo33q53kTD3ZAZzaleoic_R12jqcEfA0nkkzDoLK-u1g6yEwvwLnGvG9Gjs-3q7LimEFJCQN2iWaPh87w0-u-Xkup9XMAC9v8_5OVLIfUo2jaama469NdNtEQiiPxSo-KnRWyN7AX1Ltg1r2kTzWUrc=).\n\nFor more information, please contact:\n\nDr. Lior Shaltiel\nChief Executive Officer and Director\nPhone: +972-52-4803034\nEmail: info@nurexone.com\n\nRusso Partners LLC\nInvestor and Media Relations – United States\n215 Park Ave S, Suite 1905\nNew York, NY 10003\nPhone: 212-845-4200\nEmail: nurexone@russopartnersllc.com\n\nDr. Eva Reuter\nInvestor Relations - Germany\nPhone: +49-69-1532-5857\nEmail: e.reuter@dr-reuter.eu\n\nFORWARD-LOOKING STATEMENTS\n\nThis press release contains “forward-looking information” and\n“forward-looking statements” within the meaning of applicable Canadian\nsecurities laws (collectively, “forward-looking statements”).\nForward-looking statements are based on expectations, estimates and\nprojections as of the date of this press release and are generally\nidentifiable by words such as “may,” “will,” “could,”\n“should,” “expect,” “plan,” “intend,” “anticipate,”\n“believe,” “estimate,” “potential,” “continue,” “advance”\nand similar expressions.\n\nForward-looking statements in this press release include statements\nconcerning: the potential scalability, repeatability and consistency of the\nCompany’s modular exosome manufacturing approach; the potential to expand\nmanufacturing capacity by operating additional standardized production units\nin parallel; the potential technical, timing, capital and risk-management\nbenefits of that approach; the Company’s plans to validate, develop and\nexpand its manufacturing capabilities through Exo-Top and with third-party\ncollaborators, including Made Scientific; the ability of the Company’s\nmanufacturing capabilities to support its internal therapeutic pipeline and\npotential business-to-business supply opportunities; future demand for naïve\nexosomes; the continued development of ExoPTEN for acute spinal cord injury\nand optic nerve damage; and the Company’s broader development, regulatory,\nclinical and commercialization plans for exosome-based therapies, exosome\nproducts and targeted delivery systems.\n\nThese forward-looking statements are based on material assumptions including\nthat: the reported production-run data and the Company’s interpretation of\nthose data are accurate and complete; the parallel production results can be\nreproduced in additional runs and at greater scale; the selected analytical\nresults are appropriate indicators of product comparability; the Company will\nbe able to validate its processes and meet applicable quality, regulatory and\nmanufacturing standards; additional bioreactors, facilities, materials,\npersonnel, funding and collaborators will be available on acceptable terms;\narrangements with Made Scientific and other counterparties will progress as\ncontemplated; demand for naïve exosomes and related services will develop;\nand the Company will be able to advance ExoPTEN and its other programs as\ncurrently contemplated.\n\nForward-looking statements are subject to known and unknown risks,\nuncertainties and other factors that may cause actual results to differ\nmaterially, including: the preliminary and limited nature of the reported\nproduction results; the risk that the results will not be reproduced in\nadditional runs or at larger scale; variability inherent in biological\nmanufacturing; the risk that parallel production will not result in consistent\nquality attributes, regulatory acceptance, lower costs, shorter timelines or\nreduced operational risk; equipment, contamination, process-failure,\nsupply-chain, facility, personnel and quality-control risks; the need for\nfurther process development, validation and technology transfer; the inability\nto secure sufficient financing, materials, personnel, facilities or\ncollaborators; delays, changes or termination affecting arrangements with Made\nScientific or other counterparties; the absence of commercial orders or\nsufficient market demand; competition and technological change; regulatory,\nclinical-development, intellectual-property and commercialization risks; and\nthe risks discussed under the heading “Risk Factors” on pages 44 to 51 of\nthe Company’s annual information form dated August 27, 2024 and other\ncontinuous disclosure documents available under the Company’s SEDAR+\nprofile, copies of which are available under the Company’s SEDAR+ profile at\nwww.sedarplus.ca.\n\nThe production results described in this press release do not establish\ncommercial-scale manufacturing capability or regulatory compliance and should\nnot be interpreted as demonstrating that the Company can manufacture products\nconsistently at commercial scale. ExoPTEN is an investigational product\ncandidate, has not been approved for commercial use or for the treatment of\nany condition by any regulatory authority, and its safety and efficacy in\nhumans have not been established. Although the Company believes that the\nexpectations and assumptions reflected in the forward-looking statements are\nreasonable, there can be no assurance that the anticipated activities,\nbenefits, demand or results will occur or be achieved. Readers should not\nplace undue reliance on forward-looking statements. Forward-looking statements\nspeak only as of the date of this press release, and the Company disclaims any\nobligation to update or revise them except as required by applicable law.\n\nNeither TSXV nor its Regulation Services Provider (as that term is defined in\nthe policies of the TSXV) accepts responsibility for the adequacy or accuracy\nof this release.\n\n(i) Particle concentration (particles/mL) needed to reduce IL-6, an\ninflammatory signaling protein, by 50%. Lower concentrations indicate greater\npotency. The results are reported as thresholds, not exact values.\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/1514c671-cc84-4bcb-82d7-b834fce40882)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-10-22T12:29:00.168073083Z","server_sent_at_ms":1792672140168},"received_at":"2026-10-22T12:29:00.335Z","source_url":null},"analysis":{"id":"164994","press_release_id":"177032","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":["preliminary results not validated at commercial scale; parallel-run repeatability not yet demonstrated"],"eventType":"operations_update","narrative":"NurExone doubled exosome production by running two bioreactors in parallel with the same production time and comparable quality metrics.\n\nThe milestone supports its modular scale-out manufacturing strategy through subsidiary Exo-Top and collaborator Made Scientific, with potential applications for both its ExoPTEN pipeline and B2B naïve exosome supply.\n\nThe company cautions the results are preliminary and do not establish commercial-scale manufacturing capability or regulatory compliance.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Scale-out manufacturing proof-of-concept de-risks future commercial supply but is early-stage."},"keyFigures":{"customDimensions":{"particle_size_nm":"135-140","exosome_yield_increase":"200% (double output via two parallel bioreactors)","purity_protein_impurities_removed":">95%"}},"quotedText":"Our goal is to make increasing exosome production straightforward and robust","namedEntities":{"people":[{"name":"Dr. Tali Kizhner","role":"Director of Research and Development"},{"name":"Dr. Lior Shaltiel","role":"CEO"}],"products":["ExoPTEN"],"companies":[{"name":"NurExone Biologic Inc.","ticker":"NRX","relationship":"filer"},{"name":"Exo-Top Inc.","relationship":"wholly owned U.S. subsidiary"},{"name":"Made Scientific","relationship":"manufacturing collaborator"}],"dollarAmounts":[]},"materialImpact":{"score":2,"reasoning":"Manufacturing scalability milestone (doubled exosome yield via parallel bioreactors) is a meaningful de-risking step for a pre-revenue biotech, but it is not a clinical, regulatory, or financial event and results are preliminary and not commercial-scale."},"tickerRelevance":{"others":[],"primary":"NRX"},"globalImportance":18,"audienceRelevance":12,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"micro-cap TSXV/OTCQB","eventGravity":"manufacturing milestone, non-clinical","issuerAuthored":true,"retailFavoriteBoost":false}},"event_type":"operations_update","event_type_secondary":null,"sentiment":"bullish","material_impact_score":2,"narrative":"NurExone doubled exosome production by running two bioreactors in parallel with the same production time and comparable quality metrics.\n\nThe milestone supports its modular scale-out manufacturing strategy through subsidiary Exo-Top and collaborator Made Scientific, with potential applications for both its ExoPTEN pipeline and B2B naïve exosome supply.\n\nThe company cautions the results are preliminary and do not establish commercial-scale manufacturing capability or regulatory compliance.","key_figures":{"customDimensions":{"particle_size_nm":"135-140","exosome_yield_increase":"200% (double output via two parallel bioreactors)","purity_protein_impurities_removed":">95%"}},"named_entities":{"people":[{"name":"Dr. Tali Kizhner","role":"Director of Research and Development"},{"name":"Dr. Lior Shaltiel","role":"CEO"}],"products":["ExoPTEN"],"companies":[{"name":"NurExone Biologic Inc.","ticker":"NRX","relationship":"filer"},{"name":"Exo-Top Inc.","relationship":"wholly owned U.S. subsidiary"},{"name":"Made Scientific","relationship":"manufacturing collaborator"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-22T12:29:05.139Z","global_importance":18,"audience_relevance":12,"importance_components":{"tickerTier":"micro-cap TSXV/OTCQB","eventGravity":"manufacturing milestone, non-clinical","issuerAuthored":true,"retailFavoriteBoost":false}},"durationMs":4791,"modelName":"glm-5.3-flashx"}}